Publication:
Corticosteroid delivery using oral mucosa equivalents for the treatment of inflammatory mucosal diseases

Simple item page
dc.contributor.authorZulfahmi Saiden_US
dc.contributor.authorCraig Murdochen_US
dc.contributor.authorJens Hansenen_US
dc.contributor.authorLars Siim Madsenen_US
dc.contributor.authorHelen E. Colleyen_US
dc.date.accessioned2024-05-29T02:26:05Z
dc.date.available2024-05-29T02:26:05Z
dc.date.issued2020
dc.descriptionEuropean Journal of Oral Sciences Volume 129 Issue 5 Page (1-12)en_US
dc.description.abstractOral lichen planus (OLP) is an immune-mediated disease of the oral mucosa with idiopathic aetiology. It is frequently treated with topical corticosteroids (applied as gels, mouthwashes, or sprays); however, the mucosal exposure times of topical corticosteroids are short because of removal by the constant flow of saliva and mechanical forces. In this study we used cell monolayers, as well as oral mucosal equivalents (OMEs) containing activated T-cells, to examine corticosteroid potency and delivery of clobetasol-17-propionate from a novel electrospun mucoadhesive patch. The OMEs displayed tight junctions, desmosomes, hemidesmosomes, and an efficient permeability barrier. Following application of corticosteroids to cells cultured as monolayers, the degree of cytotoxicity measured correlated to the level of potency recognized for each corticosteroid; by contrast, OMEs were largely unaffected by corticosteroid treatment. Permeation of clobetasol-17-propionate into and through the OMEs was time- and dose-dependent, regardless of whether this corticosteroid was delivered in liquid form or from a mucoadhesive patch, and both liquid- and patch-delivered clobetasol-17-propionate significantly reduced the secretion of interleukin-2 by activated T-cells. This study confirms that OMEs are more suitable models than cell monolayers for evaluating toxicity and drug delivery. After topical exposure, clobetasol-17-propionate accumulated in OMEs at a higher level than betamethasone-17-valerate and hydrocortisone-17-valerate, and exerted its immunosuppressive actions following application via the patch delivery system, highlighting the efficacy of this mode of drug delivery to treat OLP.en_US
dc.identifier.citationSaid, Z., Murdoch, C., Hansen, J., Siim Madsen, L. and Colley, H.E. (2021), Corticosteroid delivery using oral mucosa equivalents for the treatment of inflammatory mucosal diseases. Eur J Oral Sci, 129: e12761. https://doi.org/10.1111/eos.12761en_US
dc.identifier.doi10.1111/eos.12761
dc.identifier.epage12
dc.identifier.issn1600-0722
dc.identifier.issue5
dc.identifier.spage1
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/epdf/10.1111/eos.12761
dc.identifier.urihttps://www.scopus.com/record/display.uri?eid=2-s2.0-85101808372&origin=resultslist&sort=plf-f&src=s&sid=752b0fbaeeaf1b86dbb5283894aae1df&sot=b&sdt=b&s=TITLE-ABS-KEY%28Corticosteroid+delivery+using+oral+mucosa+equivalents+for+the+treatment+of+inflammatory+mucosal+diseases%29&sl=119&sessionSearchId=752b0fbaeeaf1b86dbb5283894aae1df
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/10562
dc.identifier.volume129
dc.language.isoen_USen_US
dc.publisherJohn Wiley & Sons Ltden_US
dc.relation.ispartofEuropean Journal of Oral Sciencesen_US
dc.subjectdrug delivery, inflammation, mouth mucosa, oral lichen planus, T- lymphocytesen_US
dc.titleCorticosteroid delivery using oral mucosa equivalents for the treatment of inflammatory mucosal diseasesen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Corticosteroid delivery using oral mucosa equivalents for the treatment of inflammatory mucosal diseases.pdf
Size:
948.44 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description:
Download

Collections

Scopus